Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Jul 21, 2021 10:59am
139 Views
Post# 33581177

RE:RE:RE:RE:RE:What's bringing us down ?

RE:RE:RE:RE:RE:What's bringing us down ?

Or, Aducanumab is just one of many failures in the field of ACH, which neither proves nor disproves it.  Taken collectively though there have been so many failures that there is still no theory arising from the hypothesis. 

Goldstein's hypothesis is that his incompetence as our CEO is excusable because Aducanumab was in limbo, the implication being that his many quality-investor connections would more than pay off his bloated consulting fees once Aducanumab rescued the entire ACH field with some modest efficacy.   

Cashman's hypothesis is more like protein misfolding is at the root of or a critical step in many neurological diseases.  This is what drives Promis' platform, but it doesn't provide Goldstein any excuse. 





 

<< Previous
Bullboard Posts
Next >>